{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:59:08Z","timestamp":1759366748640,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":219,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.4103\/ijmm.ijmm_20_358","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T04:09:00Z","timestamp":1604462940000},"page":"252-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Convalescent Plasma \u2013 Is it Useful for Treating SARS Co-V2 infection?"],"prefix":"10.1016","volume":"38","author":[{"given":"Sudha","family":"Ranganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranganathan N.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"International Corona Virus Disease. Situation Report 144","key":"10.4103\/ijmm.IJMM_20_358_bib1"},{"key":"10.4103\/ijmm.IJMM_20_358_bib2","unstructured":"University of Oxford, The Oxford COVID-19 Evidence Service Team. When will it be over? An Introduction to Viral Reproduction Numbers, R0 and Re. Available from: http:\/\/www.cebm.net\/oxford-covid-91\/. [Last accessed on 2020 Jun 01]."},{"key":"10.4103\/ijmm.IJMM_20_358_bib3","first-page":"55","article-title":"Pathogenesis of COVID-19 from a cell biology perspective","author":"Mason","year":"2020","journal-title":"Eur Respir J"},{"key":"10.4103\/ijmm.IJMM_20_358_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/v12040372","article-title":"Virology, epidemiology, pathogenesis, and control of COVID-19","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses"},{"key":"10.4103\/ijmm.IJMM_20_358_bib5","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The imnumology of COVID-19: Is immune modulation an option for treatment?","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalised with severe COVID-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.4103\/ijmm.IJMM_20_358_bib7","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non\u2013randomised clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.4103\/ijmm.IJMM_20_358_bib8","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent plasma to treat COVID-19: Possibilities and challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"10.4103\/ijmm.IJMM_20_358_bib9","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.4103\/ijmm.IJMM_20_358_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.mcna.2012.04.001","article-title":"Immunotherapy in clinical medicine: Historical perspective and current status","volume":"96","author":"Shahani","year":"2012","journal-title":"Med Clin North Am"},{"key":"10.4103\/ijmm.IJMM_20_358_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2010.09.012","article-title":"Mechanisms of immunotherapy: A historical perspective","volume":"105","author":"Shakir","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib12","first-page":"152","article-title":"Convalescent plasma: New evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus"},{"key":"10.4103\/ijmm.IJMM_20_358_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_358_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience","volume":"23","author":"Ko","year":"2018","journal-title":"Antivir Ther"},{"key":"10.4103\/ijmm.IJMM_20_358_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tracli.2015.12.003","article-title":"Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow","volume":"23","author":"Garraud","year":"2016","journal-title":"Transfus Clin Biol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.transci.2014.10.003","article-title":"Ebola virus convalescent blood products: Where we are now and where we may need to go","volume":"51","author":"Burnouf","year":"2014","journal-title":"Transfus Apher Sci"},{"key":"10.4103\/ijmm.IJMM_20_358_bib17","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent plasma in Covid-19: Possible mechanisms of action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.4103\/ijmm.IJMM_20_358_bib18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","volume":"9","author":"Sun","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.4103\/ijmm.IJMM_20_358_bib19","doi-asserted-by":"crossref","unstructured":"Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralising antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020 Available at oi: https:\/\/doi.org\/10.1101\/2020.03.30.20047365.","DOI":"10.1101\/2020.03.30.20047365"},{"key":"10.4103\/ijmm.IJMM_20_358_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbi.2020.05.057","article-title":"The role of IgA in COVID-19","volume":"87","author":"Chao","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.4103\/ijmm.IJMM_20_358_bib21","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.4103\/ijmm.IJMM_20_358_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1385\/CRIAI:29:3:207","article-title":"Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation","volume":"29","author":"Lutz","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nm836","article-title":"F(ab)\u20192 mediated neutralisation of C3a and C5a anaphylatoxins: A novel effector function of immunoglobulins","volume":"9","author":"Basta","year":"2003","journal-title":"Nat Med"},{"key":"10.4103\/ijmm.IJMM_20_358_bib24","unstructured":"File No X11026\/78\/2020-BD Government of India, Directorate General of Health Services Central Drug Standard Control Organisation. Clinical trial of Convalescent Plasma in COVID-19. Version 1.1; 12 April, 2020."},{"year":"2020","series-title":"Points to Consider in the Preparation and Transfusion of COVID-19 Convalescent Plasma in Low- and Middle Income Countries","author":"Smid","key":"10.4103\/ijmm.IJMM_20_358_bib25"},{"key":"10.4103\/ijmm.IJMM_20_358_bib26","first-page":"163","article-title":"Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19","volume":"18","author":"Accorsi","year":"2020","journal-title":"Blood Transfus"},{"year":"1945","series-title":"Drugs and Cosmetics Act 1940 and Rules","key":"10.4103\/ijmm.IJMM_20_358_bib27"},{"key":"10.4103\/ijmm.IJMM_20_358_bib28","series-title":"Technical Manual of the American Association of Blood Banks","first-page":"120","article-title":"Allogenic and autologous blood donor selection","author":"Eder","year":"2014"},{"key":"10.4103\/ijmm.IJMM_20_358_bib29","unstructured":"Investigational COVID-19 Convalescent Plasma Guidance for Industry US Department of Health and Human Services Food and Drug Administration Centre for Biologics Evaluation and Research April 2020; Updated 1 May, 2020."},{"key":"10.4103\/ijmm.IJMM_20_358_bib30","unstructured":"Available from: https:\/\/www.nhsbt.nhs.uk\/how-you-can-help\/convalescent-plasma-clinical-trial. [Last accessed on 2020 Jun 07]."},{"key":"10.4103\/ijmm.IJMM_20_358_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1473-3099(20)30235-8","article-title":"SARS-CoV-2: virus dynamics and host response","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Inf Dis"},{"key":"10.4103\/ijmm.IJMM_20_358_bib32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study","volume":"20","author":"To","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_358_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.it.2020.03.007","article-title":"Neutralising antibodies against SARS- Co V-2 and other Human Coronaviruses","volume":"41","author":"Jiang","year":"2020","journal-title":"Trends Immunol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS \u2013CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"10.4103\/ijmm.IJMM_20_358_bib35","series-title":"MERS Coronavirus: Methods and Protocols, Methods in Molecular Biology","first-page":"107","article-title":"Evaluation of MERC- CoV neutralising antibodies in sera using liver virus micro-neutralisation assay","author":"Algaissi","year":"2020"},{"key":"10.4103\/ijmm.IJMM_20_358_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1086\/423286","article-title":"Neutralising Antibodies in patients with severe Acute respiratory syndrome \u2013 Associated coronavirus infection","volume":"190","author":"Nie","year":"2004","journal-title":"J Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_358_bib37","first-page":"942","article-title":"Letter: Change in trypsin sensitivity during structural rearrangements in biological membranes","volume":"20","author":"Adzerikho","year":"1975","journal-title":"Biofizika"},{"key":"10.4103\/ijmm.IJMM_20_358_bib38","first-page":"ciaa489","article-title":"Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Qu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_358_bib39","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.4103\/ijmm.IJMM_20_358_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.4103\/ijmm.IJMM_20_358_bib41","unstructured":"European Commission Directorate General for Health and Food Safety. An EU Programme of COVID-19 Convalescent Plasma Collection and Transfusion. Guidance on Collection, Testing, Processing, Storage, Distribution and Monitored use. Version 1.0; 04 April, 2020."},{"key":"10.4103\/ijmm.IJMM_20_358_bib42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00134-016-4601-3","article-title":"Assessment of heart rate, acidosis, consciousness, oxygenation and respiratory rate to predict non invasive ventilation failure in hypoxemic patients","volume":"43","author":"Duan","year":"2017","journal-title":"Int Care Med"},{"key":"10.4103\/ijmm.IJMM_20_358_bib43","unstructured":"Available from: Protocol for the use of Convalescent Plasma for the Treatment of COVID-19 Infected Patients. Available from: https:\/\/www.isbtweb.org\/fileadmin\/user_upload\/Qatar.pdf. [Last accessed on 2020 Jun 07]."},{"key":"10.4103\/ijmm.IJMM_20_358_bib44","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Depolyment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"key":"10.4103\/ijmm.IJMM_20_358_bib45","series-title":"editors. American Association of Blood Banks","first-page":"665","article-title":"Non infectious complications in blood transfusion","author":"Mazzie","year":"2014"},{"key":"10.4103\/ijmm.IJMM_20_358_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmrv.2020.04.001","article-title":"Convalescent plasma: Therapeutic Hope or Hopeless strategy in the SARS\u2013Co-V-2 Pandemic","author":"Sullivan","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.4103\/ijmm.IJMM_20_358_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41577-020-0321-6","article-title":"The potential danger of suboptimal antibody responses in COVID-19","volume":"20","author":"Iwasaki","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib48","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.4103\/ijmm.IJMM_20_358_bib49","unstructured":"Dzik S. COVID-19 convalescent plasma: Now is the time for better science. Transfus Med Rev 2020. Doi:10.106\/j.tmrv.2020.04.002."},{"key":"10.4103\/ijmm.IJMM_20_358_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life- threatening COVID-19. A randomised clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"10.4103\/ijmm.IJMM_20_358_bib51","doi-asserted-by":"crossref","unstructured":"Bloch EM, Goel R, Wendel S, Burnouf T, Al-Riyami AZ, Ang AL, et al. Guidance for the procurement of COVID-19 convalescent plasma: Differences between high- and low-middle-income countries. Vox Sang 2020. Doi: 10.111\/vox.12970.","DOI":"10.1111\/vox.12970"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720315292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085720315292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:19:04Z","timestamp":1759346344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085720315292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":51,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0255085720315292"],"URL":"https:\/\/doi.org\/10.4103\/ijmm.ijmm_20_358","relation":{},"ISSN":["0255-0857"],"issn-type":[{"type":"print","value":"0255-0857"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Convalescent Plasma \u2013 Is it Useful for Treating SARS Co-V2 infection?","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4103\/ijmm.IJMM_20_358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 Indian Journal of Medical Microbiology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}